Section of Microbiology, Department of Pathology and Laboratory Medicine, University of Parma, Parma, Italy.
Future Med Chem. 2011 Jul;3(9):1209-31. doi: 10.4155/fmc.11.71.
The incidence of life-threatening viral and microbial infections has dramatically increased over recent decades. Despite significant developments in anti-infective chemotherapy, many issues have increasingly narrowed the therapeutic options, making it imperative to discover new effective molecules. Among them, small peptides are arousing great interest. This review will focus in particular on a killer peptide, engineered from an anti-idiotypic recombinant antibody that mimics the activity of a wide-spectrum antimicrobial yeast killer toxin targeting β-glucan cell-wall receptors. The in vitro and in vivo antimicrobial, antiviral and immunomodulatory activities of killer peptide and its ability to spontaneously and reversibly self-assemble and slowly release its active dimeric form over time will be discussed as a novel paradigm of targeted auto-delivering drugs.
近年来，危及生命的病毒和微生物感染的发病率显著增加。尽管抗感染化学疗法有了重大发展，但许多问题越来越限制了治疗选择，因此必须发现新的有效分子。在这些分子中，小肽引起了极大的兴趣。这篇综述将特别关注一种杀伤肽，它由一种抗独特型重组抗体工程化而来，该抗体模拟了一种广谱抗微生物酵母杀伤毒素的活性，该毒素针对β-葡聚糖细胞壁受体。将讨论杀伤肽的体外和体内抗微生物、抗病毒和免疫调节活性及其自组装和随时间缓慢释放其活性二聚体形式的能力，这将作为一种新型靶向自递药的范例。
